/
Pharmaceutical preparations company · DE · FY ends Dec · Revenue $32M · -577.46% margin · -$148M FCF
The business is unprofitable at the operating level (-11.16% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue up 404.5% YoY with margins expanding 266.1pp.
Insufficient data to identify specific risks. Treat any missing metrics as a data gap, not a clean bill of health.
Profitability & Returns
Revenue (TTM)
$32M
▲ +404.5% YoY
Net Income (TTM)
-$170M
▲ +92.3% YoY
Op. Margin
-577.46%
▲ +266.1pp YoY
ROIC
-41.57%
▲ +34.5pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$148M
▲ +151.6% YoY
Op. Cash Flow (TTM)
-$147M
▲ +152.5% YoY
Net Debt
-$340M
Net Cash Position
Cash & Equiv.
$344M
3Y CAGR: +145.9%
Continue Research